Synlett 2012; 23(11): 1564-1574
DOI: 10.1055/s-0031-1290425
account
© Georg Thieme Verlag Stuttgart · New York

Process Research and Development for Heterocyclic p38 MAP Kinase Inhibitors

Authors

  • Oliver R. Thiel*

    Chemical Process Research and Development, Amgen Inc., One Amgen Center Drive, Thousand Oaks, California 91320, USA, Fax: +1(805)3754532   Email: othiel@amgen.com
  • Michal Achmatowicz

    Chemical Process Research and Development, Amgen Inc., One Amgen Center Drive, Thousand Oaks, California 91320, USA, Fax: +1(805)3754532   Email: othiel@amgen.com
  • Robert M. Milburn

    Chemical Process Research and Development, Amgen Inc., One Amgen Center Drive, Thousand Oaks, California 91320, USA, Fax: +1(805)3754532   Email: othiel@amgen.com
Further Information

Publication History

Received: 17 February 2012

Accepted after revision: 26 March 2012

Publication Date:
11 June 2012 (online)


Graphical Abstract

Preview

Dedicated to Professor Barry M. Trost on the occasion of his 70th birthday.

Abstract

The need to access different heterocyclic cores as part of p38 MAP kinase inhibitors led to the discovery and development of several efficient approaches to three separate classes of heterocycles, namely phthalazines, pyrazolopyridinones, and triazolopyridines. This account summarizes our studies in this field in a comprehensive fashion.

1 Introduction

2 Synthesis of Phthalazine-Based p38 Inhibitors

2.1 Synthesis of Clinical Candidate 2

2.2 Synthesis of Clinical Candidate 3

3 Synthesis of Pyrazolopyridinone-Based p38 Inhibitors

4 Synthesis of Triazolopyridine-Based p38 Inhibitors

4.1 Synthesis through Pd-Catalyzed Benzhydrazide Couplings

4.2 Synthesis through Pd-Catalyzed Benzhydrazone Couplings

5.0 Conclusions